Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care CNS Step Therapy Coverage Update | Op…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    2026 Step Therapy Criteria — select CNS drugs (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy coverage rules for several classes of central nervous system medications (antidepressants, oral antipsychotics, dextromethorphan/bupropion products, and trazodone) for Fidelis Care members and specifies prerequisite drug trials required for coverage.

    Policy Summary
    PayerFidelis Care
    Policy2026 Step Therapy Criteria — select CNS drugs (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trials per step rules (e.g., record at least a 1-day supply of required Step 1 drugs within the prior 180 days to support Step 2 approval).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4therapy sections
    2step levels
    180lookback (days)

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Antidepressants — Initial/Step 2

    Covered when the Step trial requirements below are met

    Antidepressant Step 2 coverage: Coverage for Step 2 antidepressant products is provided if ONE Step 1 drug has been tried (at least a 1-day supply in the prior 180 days).1 drug tried within prior 180 days

    Approve Exxua without prerequisite for suicidal ideation or if currently/previously taking Exxua.

    Antipsychotics (oral) — Initial/Step 2

    Covered when the Step trial requirements below are met

    Antipsychotic Step 2 coverage: Coverage for Step 2 oral antipsychotic products (e.g., Fanapt) is provided if TWO Step 1 oral antipsychotic drugs have been tried (each at least a 1-day supply in the prior 180 days).2 drugs tried within prior 180 days

    Approve Fanapt if patient is currently taking Fanapt or has taken Fanapt in the past.

    Dextromethorphan/bupropion — Initial/Step 2

    Covered when the Step trial requirements below are met

    Auvelity coverage: Coverage for Auvelity is provided if the patient has tried (1) a generic SSRI or SNRI AND (2) bupropion (each at least a 1-day supply in the prior 180 days).SSRI/SNRI + bupropion tried within prior 180 days

    Approve Auvelity for suicidal ideation without prerequisite trials or if currently/previously taking Auvelity.

    Trazodone — Step listing

    Step therapy product lists

    Trazodone Step products: Step 1 lists trazodone 100 mg and 150 mg tablets; Step 2 lists Raldesy oral solution.none specified

    No additional step criteria provided in this document portion.

    Approval conditions for Raldesy

    Coverage for Raldesy is provided when ANY of the following are met

    Step therapy and exceptions: 1) Patient has tried a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days). 2) Patient has difficulty swallowing tablets or cannot swallow tablets. 3) Patient is currently taking Raldesy or has taken Raldesy at any time in the past.see individual conditions

    Step 1 lists tablet strengths 50 mg, 100 mg, 150 mg; Step 2 is Raldesy 10 mg/mL oral solution

    Special-case approvals allow bypass of the usual step requirements in defined circumstances. For antidepressant Step 2 products, Exxua may be approved without a prior Step 1 trial when the patient has documented suicidal ideation or is currently taking (or has previously taken) Exxua. Likewise, for oral antipsychotic Step 2 products, approval may be granted if the member is currently taking (or has previously taken) the Step 2 product (for example, Fanapt). For dextromethorphan/bupropion (Auvelity), Auvelity may be approved without prior trials when the patient has suicidal ideation or is currently/previously taking Auvelity. These exceptions are limited to the products and circumstances specified in the policy.

    No explicit exclusions are listed in the cited portions of this policy. The trazodone/Raldesy sections provide step lists and approval conditions but do not identify additional drugs, diagnoses, or member groups that are excluded from coverage in these chunks.

    Coverage for Raldesy (trazodone 10 mg/mL oral solution) requires documentation that one of the Step 1 tablet forms of generic trazodone was tried — defined as at least a 1-day supply within the prior 180 days. If there is no record of such a tablet trial, approval may still be granted only if the provider documents that the patient cannot swallow tablets or has difficulty swallowing tablets, or if the member is currently taking Raldesy or has taken Raldesy at any time in the past. Absent any of these conditions, use of Raldesy without a prior tablet trial may be considered not meeting the step therapy requirement.

    Step therapy agentsNDC|plain
    trazodone 100 mg tabletListed Step 1 agent
    trazodone 150 mg tabletListed Step 1 agent
    trazodone 50 mg tabletListed in details as a tablet strength
    Raldesy 10 mg/mL oral solutionStep 2 agent (oral solution)

    Coding and Lookback

    Prior trial lookback
    ThresholdAt least a 1-day supply of the prior Step 1 drug within the previous 180 days
    WindowPrior 180 days from date of request
    Minimum supply1-day supply counts as a qualifying trial
    Applies toStep 2 antidepressant approvals (see Exxua exception)
    Prior trial look-back
    ThresholdAt least a 1-day supply of a trazodone tablet within the prior 180 days
    WindowPrior 180 days from date of request
    Minimum supply1-day supply of any listed tablet strength qualifies (50 mg, 100 mg, 150 mg)
    Applies toPrior tablet trial requirement for Raldesy Step 2 coverage

    Provider Actions and Documentation Requirements

    Prior Authorization

    Antidepressants — Step 1 prerequisite

    Step 2 antidepressant products require evidence that the member has tried ONE Step 1 antidepressant (at least a 1‑day supply within the prior 180 days). Exxua may be approved without a prior Step 1 trial if the patient has documented suicidal ideation or is currently/previously taking Exxua.

    • Acceptable Step 1 agents include listed generics such as bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine IR/ER.
    • Document at least a 1‑day supply of the Step 1 agent within the prior 180 days to satisfy the prerequisite.
    Prior Authorization

    Antipsychotics (oral) — Step 1 prerequisite

    Step 2 oral antipsychotic products require documentation that the member has tried TWO Step 1 oral antipsychotic drugs (each at least a 1‑day supply within the prior 180 days). Approve Fanapt if the patient is currently taking Fanapt or has taken Fanapt in the past.

    • Step 1 oral antipsychotics include listed agents such as aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, ziprasidone, etc.
    • Each Step 1 trial must be at least a 1‑day supply within the prior 180 days.
    Prior Authorization

    Dextromethorphan/bupropion — Step prerequisite

    Coverage for Auvelity (dextromethorphan/bupropion) requires documentation that the patient tried a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply in the prior 180 days). Auvelity may be approved without prerequisite trials for documented suicidal ideation or if the patient is currently/previously taking Auvelity.

    • Acceptable Step 1 agents include listed SSRIs/SNRIs and bupropion formulations (see Step 1 list).
    • Record at least a 1‑day supply of each required Step 1 agent within the prior 180 days to meet the prerequisite.
    Prior Authorization

    Step therapy prior authorization for Raldesy

    Prior authorization for Raldesy requires evidence that step therapy criteria are met: a prior trial of a generic trazodone tablet (50, 100, or 150 mg) with at least a 1‑day supply in the prior 180 days, or documentation of inability to swallow tablets, or current/prior use of Raldesy.

    • If a prior tablet trial cannot be documented, provide documentation of swallowing impairment or evidence the member is currently/previously taking Raldesy.
    • Tablet strengths listed for Step 1 include 50 mg, 100 mg, and 150 mg.
    Step Therapy

    Antidepressants — Step therapy rules

    For antidepressant step therapy, ensure one Step 1 generic antidepressant from the listed agents has been tried (at least a 1‑day supply in the prior 180 days) before requesting Step 2 products. Exxua is an exception and may be approved without the prerequisite for suicidal ideation or documented current/prior Exxua use.

    • Step 1 list includes bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine IR/ER.
    • Document the 1‑day supply within 180 days in the medical record or pharmacy history.
    Step Therapy

    Antipsychotics (oral) — Step therapy rules

    For oral antipsychotic step therapy, ensure two distinct Step 1 oral antipsychotic trials (each ≥1‑day supply within the prior 180 days) are documented before requesting Step 2 agents; Fanapt may be approved without Step 1 trials if current/prior Fanapt use is documented.

    • Step 1 agents include oral formulations of aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, ziprasidone, and others listed.
    • Each Step 1 trial must be verifiable as at least a 1‑day supply in the prior 180 days.
    Step Therapy

    Dextromethorphan/bupropion — Step therapy rules

    Auvelity Step 1 requires trials of both a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply in the prior 180 days); Step 2 includes Auvelity and other listed agents. Approve Auvelity without prerequisites for suicidal ideation or documented current/prior Auvelity use.

    • Confirm pharmacy fill records or provider documentation showing a 1‑day supply for each required agent within 180 days.
    • If suicidal ideation is documented, note that prerequisite trials can be bypassed per policy.
    Step Therapy

    Trazodone — Step therapy rules

    Trazodone step therapy: Step 1 includes trazodone tablets (100 mg and 150 mg); Step 2 is Raldesy 10 mg/mL oral solution. A prior tablet trial (at least a 1‑day supply in the prior 180 days) is required unless swallowing impairment or prior/current Raldesy use is documented.

    • Step 1 tablet strengths include 50 mg (also listed), 100 mg, and 150 mg.
    • If unable to swallow tablets, document the clinical reason to support approval of Raldesy without a tablet trial.
    Step Therapy

    Step therapy structure — Raldesy

    Step therapy structure for Raldesy is two-tiered: Step 1 requires a trial of a generic trazodone tablet (50, 100, or 150 mg) with at least a 1‑day supply within the prior 180 days; Step 2 is Raldesy oral solution (10 mg/mL) which may be authorized if Step 1 is met or an exception applies (swallowing difficulty or current/prior Raldesy use).

    • Record of the tablet trial (≥1‑day supply within 180 days) or documentation of swallowing impairment or prior Raldesy use must be provided for Step 2 approval.
    • Tablet strengths enumerated for Step 1: 50 mg, 100 mg, 150 mg.
    Documentation Required

    Antidepressants — documentation of trial

    Documented trials must show at least a 1‑day supply of the listed Step 1 drug within the prior 180 days to satisfy prerequisites for Step 2 antidepressant approvals; absence of such documentation may result in denial.

    • Record the date, medication name and strength, and evidence of fill or administration to demonstrate the 1‑day supply within 180 days.
    Documentation Required

    Antipsychotics (oral) — documentation required

    For Step 2 oral antipsychotic requests, provide documentation that two distinct Step 1 oral antipsychotic drugs were taken (each at least a 1‑day supply within the prior 180 days) or provide evidence of current/past use of the Step 2 product (Fanapt) to qualify for approval.

    • Documentation can include pharmacy fill history, medication administration records, or provider notes specifying dates and quantities to demonstrate at least a 1‑day supply within 180 days.
    Documentation Required

    Dextromethorphan/bupropion — documentation required

    For Auvelity requests, document that the patient tried a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply in the prior 180 days), or provide documentation of suicidal ideation or current/prior Auvelity use to allow bypass of prerequisites.

    • Acceptable evidence includes pharmacy fills, provider chart notes, or medication lists showing the required agents and dates that satisfy the 180‑day lookback.
    Documentation Required

    Required documentation for Raldesy

    For Raldesy, provide a record of prior use of a trazodone tablet (at least a 1‑day supply in the last 180 days), or document inability to swallow tablets, or show prior/current use of Raldesy to support approval.

    • If relying on swallowing impairment, include clinical notes describing the impairment or a swallow assessment.
    • If relying on prior Raldesy use, include prior medication records showing Raldesy dispensing or administration.
    Denial Risk

    Antidepressants — denial risk for missing Step trial

    Failure to document that one Step 1 drug was tried (at least a 1‑day supply in the prior 180 days) for antidepressant Step 2 requests may result in denial of coverage.

    • Ensure pharmacy fill data or chart notes are submitted with the prior authorization to avoid denial.
    Denial Risk

    Antipsychotics (oral) — denial risk for missing Step trials

    Lack of documentation that two Step 1 oral antipsychotic drugs were tried (each at least a 1‑day supply in the prior 180 days) may lead to denial of Step 2 oral antipsychotic coverage; documenting current or prior use of Fanapt is an alternative route to approval.

    • Provide fill records or provider documentation for both Step 1 agents to mitigate denial risk.
    Denial Risk

    Dextromethorphan/bupropion — denial risk for missing Step trials

    Coverage for Auvelity requires prior trials of a generic SSRI or SNRI AND bupropion (each at least a 1‑day supply in the prior 180 days); absence of these documented trials may result in denial unless suicidal ideation or prior/current Auvelity use is documented.

    • Submit documentation of both required trials or clinical justification to avoid denial.
    Denial Risk

    Raldesy — denial risk for missing prior tablet trial

    Coverage for Raldesy requires documentation of a prior trial of a tablet dosage form of generic trazodone (at least a 1‑day supply within the prior 180 days); absence of that trial and lack of documentation of an exception (swallowing impairment or prior Raldesy use) may trigger denial.

    • Provide prior fill records or clinical documentation of tablet intolerance/swallowing difficulty or prior Raldesy exposure to support approval.

    Background

    This policy section defines the two-step structure used to authorize selected central nervous system drugs. It lists Step 1 (preferred/generic) agents and the Step 2 (brand/alternative) products, and specifies the prerequisite trial logic required for Step 2 coverage. A documented trial is defined as at least a 1-day supply within the prior 180 days. The document provides examples across classes: antidepressant Step 2 coverage is allowed if one Step 1 antidepressant was tried (or Exxua exceptions apply); oral antipsychotic Step 2 coverage requires two Step 1 oral antipsychotic trials (or current/prior Fanapt use); Auvelity requires trials of a generic SSRI or SNRI and bupropion (with exceptions for suicidal ideation or prior/current Auvelity use); and trazodone Step 1 tablet strengths (50 mg, 100 mg, 150 mg) are the prerequisite for Raldesy oral solution unless swallowing impairment or prior Raldesy use is documented.

    Definitions

    Step trial (definition)
    DefinitionA documented trial defined as at least a 1-day supply of a Step 1 drug within the prior 180 days used to satisfy prerequisite requirements for Step 2 coverage.
    Evidence acceptedPharmacy claim or medical record showing ≥1-day supply within prior 180 days
    ScopeUsed across antidepressant, oral antipsychotic, and dextromethorphan/bupropion Step requirements
    Suicidal ideation exception
    Policy exceptionCertain Step 2 drugs (Exxua and Auvelity) may be approved without prerequisite Step 1 trials if the patient has documented suicidal ideation.
    Alternate approval routesAlso allow approval if the member is currently taking or has previously taken the Step 2 product
    Applies toExxua (antidepressant) and Auvelity (dextromethorphan/bupropion)
    Raldesy
    ProductRaldesy 10 mg/mL oral solution (trazodone oral solution)
    Step placementListed as Step 2 agent — oral solution formulation
    Approval conditionsCovered when patient has tried a trazodone tablet (≥1-day supply in prior 180 days), cannot swallow tablets, or currently/previously took Raldesy
    Generic trazodone tablet
    Strengths listedTrazodone tablets: 50 mg, 100 mg, 150 mg
    RoleStep 1 prerequisite agents for Raldesy Step 2 coverage
    Qualifying trialAt least a 1-day supply of any listed tablet strength within prior 180 days satisfies Step 1 requirement

    Initial Therapy (Step 1) Criteria

    Step 1 (Initial therapy) products

    Step 1 (preferred/generic) products

    Antidepressant Step 1: Lists of preferred/generic antidepressants (see policy Step 1 list: bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine IR/ER).none

    A single trial of these products counts toward Step 2 prerequisites.

    Dextromethorphan/bupropion Step 1: Includes bupropion and multiple SSRIs/SNRIs (see policy Step 1 list).none

    Both an SSRI/SNRI and bupropion must be tried to allow Auvelity.

    Trazodone Step 1: Trazodone 100 mg and 150 mg tablets listed as Step 1 agents.none

    Initial therapy (Step 1)

    Initial therapy requirement

    Step 1 requirement: Patient must have tried a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days).>=1 day supply within 180 days

    Tablet strengths include 50 mg, 100 mg, 150 mg

    Continuation Therapy Criteria

    Continuation therapy

    Continuation/maintenance use

    Continuation: Approve if the patient is currently taking Raldesy or has taken Raldesy at any time in the past.any prior use

    Covers continuation without requiring additional tablet trial

    Step Therapy Summary Tables

    TherapyStep requirementException / special-case approvals
    Antidepressants (Step 2 products, e.g., branded or non-preferred formulations)One Step 1 drug trial required (documented as at least a 1-day supply in the prior 180 days).Exxua may be approved without prerequisite trials if the patient has suicidal ideation or is currently/previously taking Exxua.
    TherapyStep requirementException / special-case approvals
    Oral antipsychotics (Step 2 products, e.g., Fanapt)Two Step 1 oral antipsychotic drug trials required (each documented as at least a 1-day supply in the prior 180 days).Approve Fanapt if the patient is currently taking Fanapt or has taken Fanapt in the past.
    TherapyStep requirementException / special-case approvals
    Dextromethorphan/bupropion (Auvelity)Patient must have tried both: (1) a generic SSRI or SNRI AND (2) bupropion (each at least a 1-day supply in the prior 180 days).Approve Auvelity without prerequisite trials if the patient has suicidal ideation or is currently/previously taking Auvelity.
    TherapyStep 1 agentsStep 2 agent
    Trazodone step listingTrazodone 100 mg tablet; trazodone 150 mg tabletRaldesy 10 mg/mL oral solution
    StepRequired evidenceAlternate criteria / exceptions
    Step 1Trial of a generic trazodone tablet (available strengths include 50 mg, 100 mg, or 150 mg) documented as at least a 1-day supply in the prior 180 days.N/A
    Step 2Raldesy 10 mg/mL oral solution may be approved after Step 1 is met.Raldesy may be approved without a prior tablet trial if the patient has difficulty swallowing tablets or cannot swallow tablets, or if the patient is currently taking Raldesy or has taken Raldesy in the past.
    Policy Summary
    PayerFidelis Care
    Policy2026 Step Therapy Criteria — select CNS drugs (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trials per step rules (e.g., record at least a 1-day supply of required Step 1 drugs within the prior 180 days to support Step 2 approval).
    SourceLink
    On This Page
    Coverage CriteriaCoding and LookbackProvider Actions and Documentation RequirementsBackgroundDefinitionsInitial Therapy (Step 1) CriteriaContinuation Therapy CriteriaStep Therapy Summary Tables